Globitair

Lilly raises outlook for third time this year as Zepbound sales soar

MarketWatch TopUnited States of America

Lilly raises outlook for third time this year as Zepbound sales soar

The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.

Read the full story at MarketWatch TopOpen in the live monitor

Related discussion groups

No group discusses this yet. Start a discussion group and attach this story.

More news about United States of America